Authors: Slingluff, CL Yamshchikov, G Neese, P Galavotti, H Eastham, S Engelhard, VH Kittlesen, D Deacon, D Hibbitts, S Grosh, WW Petroni, G Cohen, R Wiernasz, C Patterson, JW Conway, BP Ross, WG

Citation: Cl. Slingluff et al., Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes, CLIN CANC R, 7(10), 2001, pp. 3012-3024

Authors: Yang, SX Kittlesen, D Slingluff, CL Vervaert, CE Seigler, HF Darrow, TL

Citation: Sx. Yang et al., Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and-A3, J IMMUNOL, 164(8), 2000, pp. 4204-4211